Interleukin-33 in tissue homeostasis, injury, and inflammation

AB Molofsky, AK Savage, RM Locksley - Immunity, 2015 - cell.com
Interleukin-33 (IL-33) is a nuclear-associated cytokine of the IL-1 family originally described
as a potent inducer of allergic type 2 immunity. IL-33 signals via the receptor ST2, which is …

Interleukin 33 is a guardian of barriers and a local alarmin

NT Martin, MU Martin - Nature immunology, 2016 - nature.com
Abstract Interleukin 33 (IL-33) is a member of the IL-1 family of cytokines with a growing
number of target cells and a plethora of biological functions. Although it has commonalities …

[HTML][HTML] The central role of IL-33/IL-1RL1 pathway in asthma: from pathogenesis to intervention

AKS Jayalatha, L Hesse, ME Ketelaar… - Pharmacology & …, 2021 - Elsevier
Abstract Interleukin-33 (IL-33), a member of the IL-1 family, and its cognate receptor,
Interleukin-1 receptor like-1 (IL-1RL1 or ST2), are susceptibility genes for childhood asthma …

Damage-associated molecular patterns in trauma

B Relja, WG Land - European journal of trauma and emergency surgery, 2020 - Springer
Abstract In 1994, the “danger model” argued that adaptive immune responses are driven
rather by molecules released upon tissue damage than by the recognition of “strange” …

[HTML][HTML] IL-33 promotes ST2-dependent lung fibrosis by the induction of alternatively activated macrophages and innate lymphoid cells in mice

D Li, R Guabiraba, AG Besnard, M Komai-Koma… - Journal of Allergy and …, 2014 - Elsevier
Background The initiation and regulation of pulmonary fibrosis are not well understood. IL-
33, an important cytokine for respiratory diseases, is overexpressed in the lungs of patients …

Tozorakimab (MEDI3506): an anti-IL-33 antibody that inhibits IL-33 signalling via ST2 and RAGE/EGFR to reduce inflammation and epithelial dysfunction

E England, DG Rees, IC Scott, S Carmen, DTY Chan… - Scientific Reports, 2023 - nature.com
Abstract Interleukin (IL)-33 is a broad-acting alarmin cytokine that can drive inflammatory
responses following tissue damage or infection and is a promising target for treatment of …

IL-33/ST2 axis in organ fibrosis

OS Kotsiou, KI Gourgoulianis… - Frontiers in …, 2018 - frontiersin.org
Interleukin 33 (IL-33) is highly expressed in barrier sites, acting via the suppression of
tumorigenicity 2 receptor (ST2). IL-33/ST2 axis has long been known to play a pivotal role in …

Cytokine-induced modulation of colorectal cancer

LF Mager, MH Wasmer, TT Rau, P Krebs - Frontiers in oncology, 2016 - frontiersin.org
The emergence of novel immunomodulatory cancer therapies over the last decade, above
all immune checkpoint blockade, has significantly advanced tumor treatment. For colorectal …

Tumoral expression of IL-33 inhibits tumor growth and modifies the tumor microenvironment through CD8+ T and NK cells

X Gao, X Wang, Q Yang, X Zhao, W Wen… - The Journal of …, 2015 - journals.aai.org
Cancer immunotherapy has shown great promise as a new standard cancer therapeutic
modality. However, the response rates are limited for current approach that depends on …

Surgical trauma‐induced immunosuppression in cancer: recent advances and the potential therapies

F Tang, Y Tie, C Tu, X Wei - Clinical and translational medicine, 2020 - Wiley Online Library
Surgical resection remains the mainstay treatment for solid cancers, especially for localized
disease. However, the postoperative immunosuppression provides a window for cancer cell …